Robert E. Dudley, Ph.D., has served as our Chief Executive Officer, President and Chairman of our board of directors since Clarus's inception in February 2004. Prior to that, from 2001 to 2003, he served as President, Chief Executive Officer, and Director of Anagen Therapeutics, Inc., a private biopharmaceutical company affiliated with the University of Chicago. He served as President, Chief Executive Officer, and Director of Unimed Pharmaceuticals, Inc. from 1999 to 2001 during which time Unimed received FDA approval for and launched AndroGel (which he co-invented). From 1994 to 2001, Dr. Dudley held several senior level executive positions at Unimed Pharmaceuticals, Inc., a public company acquired by Solvay Pharmaceuticals in 1999. Dr. Dudley has over 25 years of experience in the field of testosterone replacement therapy, has published numerous articles in peer-reviewed medical journals, and is an inventor on several testosterone-related patents – including those patents that cover Clarus' oral TU formulations.
Dr. Dudley received his B.S. in Biology from Pepperdine University, Seaver College, his M.S. in Biology from University of New Mexico, and his Ph.D., with honors, in Pharmacology and Toxicology from the University of Kansas School of Medicine. Dr. Dudley is also a board-certified toxicologist.
James is a co-founder of Thomas, McNerney & Partners and has been investing in health care companies since 1992. James previously headed Warburg Pincus LLC's medical technology private equity practice, where he had responsibility for investments in biotechnology, pharmaceutical, medical device and diagnostic companies. Prior to joining Warburg, James was a Vice President at Goldman Sachs International in London. He is currently a board member of CAS Medical Systems, Inc. (CASM), Clarus Therapeutics, Inc. and Keystone Dental, Inc.. Historical investments include: American Medical Systems Holdings, Inc. (AMMD), Coley Pharmaceutical Group, Inc. (COLY sold to Pfizer), Galil Medical Ltd. (sold to BTG plc), The Medicines Company (MDCO), OsteoBiologics, Inc. (sold to Smith & Nephew plc), Torax Medical, Inc. (sold to Johnson and Johnson), Transkaryotic Therapies, Inc. (TKTX sold to Shire Pharmaceuticals Group plc), Wright Medical Group, Inc. (WMGI), and Xomed Surgical Products, Inc. (XOMD sold to Medtronic, Inc.). James graduated magna cum laude with a B.S. in Economics from the Wharton School at the University of Pennsylvania and received an M.Sc. in Economics from the London School of Economics.
Alex joined H.I.G. BioHealth Partners as a Managing Director in January 2016. He currently serves on the board of directors for Clarus Therapeutics and Keystone Dental. Prior to H.I.G., Alex spent 13 years at Thomas, McNerney & Partners. Previous board seats included Auspex Pharmaceuticals (sold to Teva), InnoPharma (sold to Pfizer), Quinnova (sold to Amneal), Celator (public), Zogenix (public), Tranzyme (merged with Ocera) and observer roles at PCI Pharma Services and Coley Pharmaceutical (sold to Pfizer). Prior to Thomas, McNerney, Alex spent 11 years in the research department at Hambrecht & Quist (and its successor firms Chase H&Q and JPMorgan). Alex is the co-chair of the Business Advisory Council of the Children's Tumor Foundation, an advisor for the Partnership Fund of NYC, which manages a bioaccelarator to advance local healthcare research, and is on the Life Sciences Council for Springboard Enterprises, a group that assists women entrepreneurs. He is also a board member for the Greenwich Council of the Boy Scouts of America. He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa.
Since 2005, Bruce C. Robertson, Ph.D., has served as a Managing Director at H.I.G. BioHealth Partners, the dedicated healthcare affiliate of H.I.G. Capital, the leading private equity firm in the lower middle market, with $21 billion under management. He previously served as a Managing Director at Toucan Capital, a healthcare-focused venture capital firm. Dr. Robertson also serves on the board of directors of a number of private companies and organizations, including Iconic Therapeutics, CardioFocus, Inc., Apollo Endosurgery, and RxSight. Dr. Robertson received a B.S.E. in Chemical Engineering from the University of Pennsylvania, an M.B.A. from Harvard Business School and a Ph.D. in Chemical/Biomedical Engineering from the University of Delaware.
Stuart Holden, M.D., has been the Chairman of ProQuest Investments' Scientific Advisory Board since its founding. Since May 2014 Dr. Holden is a member of the UCLA faculty as a Health Sciences Clinical Professor of Urology, Spielberg Family Chair in Urologic Oncology, in the Department of Urology at the UCLA David Geffen School of Medicine and Associate Director of the UCLA Institute of Urologic Oncology. Dr. Holden has worked on the frontlines of prostate cancer for more than 36 years and has pioneered new treatments for urologic cancers. Dr. Holden's dedication to patient care resulted in him being named medical director of the Prostate Cancer Foundation, which is the world's largest prostate cancer research funding organization; he has held this position since the foundation's inception in 1993. Dr. Holden was the director of the Louis Warschaw Prostate Cancer Center at Cedars-Sinai Medical Center and the first holder of the Warschaw, Robertson, Law Families Chair in Prostate Cancer. In addition, he was a founding partner at Tower Urology in Los Angeles. Dr. Holden received a B.A. degree from the University of Wisconsin-Madison and completed his medical degree and received his surgical training at Weill Cornell Medical College and the New York Hospital – Cornell University Medical College. He completed his urology residency at Emory University School of Medicine and fellowships in urology and developmental genetics at Memorial Sloan-Kettering Cancer Center. He also was awarded a clinical fellowship from the American Cancer Society. Dr. Holden also serves on the board of directors of Urogen Pharma Ltd.
Since December 2013, Mengjiao Jiang has served as Partner of C-Bridge Capital Partners LLC, a China-based investment management firm focused on healthcare investments, which she co-founded. Prior to that, Ms. Jiang served from March 2012 to December 2013 as Chief Operating Officer and Director in the Principal Investments Group of Far East Horizon Ltd., a leasing company in China. Ms. Jiang previously was Managing Director at the Shanghai-based investment manager, ARC China, where she established its China operations, from March 2008 to June 2012. Ms. Jiang received a B.A. in economics and political science from Wellesley College.
Elizabeth A. Cermak serves as a member of our board of directors. Ms. Cermak also serves as a Board Member for SteadyMed Therapeutics, where she also Chairs the Compensation Committee and is a member of the Audit Committee. Most recently, Ms. Cermak was Executive Vice President, Chief Commercial Officer and member of the Executive Committee of POZEN, Inc. Prior to that, Ms. Cermak served as the Worldwide Vice President of Global Marketing for Personal Products, a segment of the Johnson & Johnson Consumer Health Care business, and also served as the Vice President of the Women's Healthcare RX Franchise for Ortho-McNeil Pharmaceutical. Ms. Cermak received her undergraduate degree from Franklin & Marshall College and an MBA from Drexel University.
Mark A. Prygocki, Sr. serves as a member of our board of directors and as Chairman of the audit committee. Mr. Prygocki currently serves as CEO and a Director of Illustris Pharmaceuticals, Inc., a privately-held bio-development company. Mr. Prygocki is a pharmaceutical industry leader with over 20 years of experience, specializing in corporate strategy and operational efficiency. He was employed by Medicis Pharmaceutical Corporation for more than 20 years and served as President from July 2010 to December 2012. Prior to that, Mr. Prygocki held several senior‐level positions at Medicis, including Chief Operating Officer, Executive Vice President, and Chief Financial Officer and Treasurer. Mr. Prygocki's previous experience includes work at Citigroup, an investment banking firm, in the regulatory reporting division. Prior to that, Mr. Prygocki spent several years in the audit department of Ernst & Young, LLP. He is certified by the Arizona State Board of Accountancy and the New York Society of CPAs. Mr. Prygocki served for over ten years on the board of Whispering Hope Ranch Foundation, a non-profit organization that assists children with special needs.